{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:43:18Z","timestamp":1792478598381,"version":"4.5.0"},"reference-count":38,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15862","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:18:51Z","timestamp":1789467531000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Combination of vinorelbine capsules and the small molecule anti\u2011angiogenic drug apatinib for first\u2011line treatment of advanced triple\u2011negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report"],"prefix":"10.3892","volume":"32","author":[{"given":"Xue","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongcun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meidi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiwen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"key20261020093221_b1-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.21037\/gs-20-209","article-title":"Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer","volume":"9","author":"Tang","year":"2020","journal-title":"Gland Surg"},{"key":"key20261020093221_b2-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"e195410","DOI":"10.1001\/jamasurg.2019.5410","article-title":"Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial","volume":"155","author":"Golshan","year":"2020","journal-title":"JAMA Surg"},{"key":"key20261020093221_b3-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20261020093221_b4-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","article-title":"A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer","volume":"54","author":"Kumar","year":"2023","journal-title":"J Adv Res"},{"key":"key20261020093221_b5-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20261020093221_b6-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"key20261020093221_b7-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4161\/15384047.2014.986973","article-title":"A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"key20261020093221_b8-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000136796","article-title":"Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer","volume":"73","author":"Laessig","year":"2007","journal-title":"Oncology"},{"key":"key20261020093221_b9-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"key":"key20261020093221_b10-ol-32-5-15862","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.ADRZ.121218","article-title":"Understanding and managing treatment adherence in schizophrenia","author":"Dufort","year":"2019","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"key20261020093221_b11-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S2215-0366(20)30262-5","article-title":"Violence and mental disorders: A structured review of associations by individual diagnoses, risk factors, and risk assessment","volume":"8","author":"Whiting","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"key20261020093221_b12-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: Molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncologist"},{"key":"key20261020093221_b13-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"key20261020093221_b14-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ijc.28829","article-title":"Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"135","author":"Hu","year":"2014","journal-title":"Int J Cancer"},{"key":"key20261020093221_b15-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"e000696","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20261020093221_b16-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"key20261020093221_b17-ol-32-5-15862","first-page":"9","article-title":"Biochemical effects of navelbine on tubulin and associated proteins","volume":"16","author":"Fellous","year":"1989","journal-title":"Semin Oncol"},{"key":"key20261020093221_b18-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0304-3835(84)90042-9","article-title":"Experimental antitumor activity of 5\u2032-nor-anhydrovinblastine navelbine","volume":"22","author":"Maral","year":"1984","journal-title":"Cancer Lett"},{"key":"key20261020093221_b19-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2165\/00002512-199405030-00006","article-title":"Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy","volume":"5","author":"Goa","year":"1994","journal-title":"Drugs Aging"},{"key":"key20261020093221_b20-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1080\/03007995.2016.1211518","article-title":"Burden of advanced breast cancer for patients and caregivers in Europe: Comparison of two treatment forms of vinorelbine, oral and intravenous","volume":"32","author":"Barni","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"key20261020093221_b21-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2011.05.005","article-title":"Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results","volume":"38","author":"Aapro","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"key20261020093221_b22-ol-32-5-15862","first-page":"35","article-title":"Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy","volume":"21","author":"Freyer","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20261020093221_b23-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00280-013-2216-8","article-title":"Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer","volume":"72","author":"Mansour","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20261020093221_b24-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.bjc.6605156","article-title":"All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: An international phase II trial","volume":"101","author":"Tubiana-Mathieu","year":"2009","journal-title":"Br J Cancer"},{"key":"key20261020093221_b25-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-008-0915-3","article-title":"Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer","volume":"64","author":"Nol\u00e8","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20261020093221_b26-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/bmj.39227.616447.BE","article-title":"Schizophrenia","volume":"335","author":"Picchioni","year":"2007","journal-title":"BMJ"},{"key":"key20261020093221_b27-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.schres.2009.07.012","article-title":"Schizophrenia and breast cancer incidence: A systematic review of clinical studies","volume":"114","author":"Bushe","year":"2009","journal-title":"Schizophr Res"},{"key":"key20261020093221_b28-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000356498","article-title":"Inverse and direct cancer comorbidity in people with central nervous system disorders: A meta-analysis of cancer incidence in 577,013 participants of 50 observational studies","volume":"83","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Psychother Psychosom"},{"key":"key20261020093221_b29-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamapsychiatry.2017.4748","article-title":"Association of schizophrenia with the risk of breast cancer incidence: A meta-analysis","volume":"75","author":"Zhuo","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"key20261020093221_b30-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.breast.2010.04.001","article-title":"Schizophrenia does not adversely affect the treatment of women with breast cancer: A cohort study","volume":"19","author":"Sharma","year":"2010","journal-title":"Breast"},{"key":"key20261020093221_b31-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1993.01820140007001","article-title":"The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services","volume":"50","author":"Regier","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"key20261020093221_b32-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"key":"key20261020093221_b33-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1741-7015-2-13","article-title":"A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology","volume":"2","author":"McGrath","year":"2004","journal-title":"BMC Med"},{"key":"key20261020093221_b34-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","article-title":"Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: The ATRACTIB phase 2 trial","volume":"31","author":"Gion","year":"2025","journal-title":"Nat Med"},{"key":"key20261020093221_b35-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2018.01.002","article-title":"Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: Assessment of immunohistochemical markers","volume":"77","author":"Hui","year":"2018","journal-title":"Hum Pathol"},{"key":"key20261020093221_b36-ol-32-5-15862","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1185\/03007995.2014.895310","article-title":"Individualized chemotherapy based on organ selectivity: A retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer","volume":"30","author":"Liu","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"key20261020093221_b37-ol-32-5-15862","first-page":"7","article-title":"Genetic evidence for the association between schizophrenia and breast cancer","volume":"3","author":"Shi","year":"2018","journal-title":"J Psychiatr Brain Sci"},{"key":"key20261020093221_b38-ol-32-5-15862","first-page":"845","article-title":"Adjuvant chemotherapy for breast cancer in patients with schizophrenia","volume":"3","author":"Hwang","year":"2012","journal-title":"Oncol Lett"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:32:27Z","timestamp":1792477947000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15862","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}